Form 4: Acrivon CDO Erick Gamelin Granted Stock Options

Acrivon Therapeutics' Chief Development Officer, Erick Gamelin, was granted 94,946 stock options with an exercise price of $1.51.

Summary

• Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc. (ACRV), was granted 94,946 stock options.
• The stock options have an exercise price of $1.51 per share.
• The grant date for these options was March 1, 2026, and they expire on February 29, 2036.
• The vesting schedule for the options is 25% on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, contingent on continuous service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a standard compensation disclosure, indicating stability in executive leadership and a continued commitment to aligning management incentives with shareholder value, without revealing any new operational or financial performance data.

Positives

• The grant of stock options to the Chief Development Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The options have a 10-year expiration date, providing a long window for potential value realization.

Negatives

• No immediate negative implications are apparent from this routine executive compensation disclosure.

Risks

• The value of the stock options is subject to the future performance of Acrivon Therapeutics' common stock, which carries inherent market and operational risks.
• The vesting schedule requires continuous service, meaning the options could be forfeited if the reporting person's employment terminates before full vesting.

Future Outlook

The vesting schedule for the stock options extends over several years, indicating an expectation of continued service from the Chief Development Officer and a long-term incentive structure tied to the company's future performance.

Management Comments

• The grant of stock options to Erick Gamelin, Chief Development Officer, reflects a standard compensation practice aimed at retaining key executives and aligning their financial interests with long-term shareholder value.

Industry Context

Stock option grants are a common component of executive compensation packages in the biotechnology and pharmaceutical industries, particularly for development-stage companies like Acrivon Therapeutics. StockSavvy.ai notes that such grants are used to attract and retain talent, incentivize innovation, and align management's financial success with the company's clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to a Chief Development Officer is a standard practice in the biotech sector, comparable to compensation structures seen at companies like Moderna, BioNTech, or Regeneron, which frequently use equity-based incentives to motivate R&D leadership.
• The vesting schedule, with an initial cliff and subsequent monthly installments, is typical for executive equity awards, ensuring long-term commitment, similar to plans observed at emerging biopharma firms such as Relay Therapeutics or Karuna Therapeutics.

Related Party Transactions

• The grant of stock options to Erick Gamelin, an officer of Acrivon Therapeutics, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Development Officer's financial interests with shareholder value creation, potentially leading to more focused efforts on company growth and stock performance.
• Employees: This type of executive compensation can set a precedent or benchmark for other employees' incentive programs, though specific impact is limited to the executive.

Next Steps

• The stock options will begin vesting on March 1, 2027, with subsequent monthly vesting installments over the following three years, subject to Erick Gamelin's continuous service.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Erick Gamelin, Stock Options, Executive Compensation, Form 4, Beneficial Ownership, Biotechnology